Williams Gregg purchased $1,000K of VANI (indirect holdings)

Williams Gregg purchased 793,650 indirectly-held shares of Vivani Medical, Inc. (VANI) at $1.26 ($1.00M total) on 2026-07-15.

Original reporting
SEC EDGAR · Williams Gregg
Published Jul 16, 2026, 1:00 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jul 16, 2026, 1:01 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$VANI
Bullish
medium confidence
Mentioned
$VANI
Relevance
6/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$VANIBullishLow
01

Why it matters

A director and 10% owner purchased 793,650 shares at $1.26 for about $1.0M, with holdings after the transaction reported as 36,912,736 shares.

02

Market read

Traders may monitor for follow-on insider activity, but the filing does not include operational or financial updates.

03

What to watch

No 10b5-1 plan is stated, but the filing does not disclose the underlying reason for the indirect purchase or whether other insiders are acting similarly.

Relevance 6/10Novelty 6/10Timing: new Form 4 filed 2026-07-16, covering a 2026-07-15 purchase

Background

This is an SEC Form 4 insider transaction for Vivani Medical, Inc. (VANI).

Company-level read

Ticker impact

$VANIBullishMedium confidence
Context

Vivani Medical director and 10% owner Williams Gregg bought 793,650 shares at $1.26 on 2026-07-15 via an indirect holding form.

Expected impact

Likely limited near-term impact; may modestly support sentiment if traders treat insider buying as a signal.

Evidence & confidence

Form 4 confirms a large dollar-value open-market purchase (~$1.0M) and no 10b5-1 plan, but insider buys alone rarely drive sustained repricing without additional disclosures.

Market effects

No sector-level read-across; this is company-specific insider activity.

None indicated.

None indicated.

Counterpoint

The purchase may reflect diversification, tax planning, or pre-existing arrangements rather than a new bullish thesis, especially with indirect holdings.

Key entities

  • Vivani Medical, Inc.

    Company whose insider transaction is disclosed on Form 4.

  • Williams Gregg

    Director and 10% owner who purchased shares via an indirect holding form.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$VANIMed

Vivani Medical Merger Closing Awaits Final Regulatory Approval

Vivani Medical's merger with Cortigent awaits final regulatory approval, with closing expected shortly after. The deal will make Cortigent a subsidiary of ClearOne. Vivani had initially targeted an October 2026 closing, but the timeline is now uncertain. The transaction may not be completed due to regulatory or other issues, according to the company.

$VANIMed

Vivani Medical Reports Second Quarter 2026 Financial Results and Provides Business Update

Vivani Medical, Inc. (VANI) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Vivani Medical Reports Second Quarter 2026 Financial Results and Provides Business Update All participants successfully dosed in SLIM-1™, the Company's first-in-human Phase 1 trial of NPM-139, a miniature, ultra long-acting semaglutide implant for chronic weight mana

$VANIMed

Vivani Flat on Hookup with Novo

Vivani Medical (NASDAQ: VANI) said it signed an agreement with Novo Nordisk to let Novo evaluate Vivani’s NPM-139 semaglutide implant using Vivani’s NanoPortal platform for chronic weight management. Vivani noted no exclusivity. It plans to start a Phase 1 first-in-human study mid-2026, using Wegovy as comparator, to support a Phase 2 dose-ranging study.

$VANIMedAI 8/10

Vivani Announces Entry into Merger Agreement Between Wholly Owned Subsidiary Cortigent, Inc. and Nasdaq-listed ClearOne, Inc.

Vivani Medical (Nasdaq: VANI) said its subsidiary Cortigent will merge into ClearOne (Nasdaq: CLRO), with Cortigent becoming a wholly owned ClearOne unit. ClearOne plans a concurrent $10–15M financing via an S-1. Vivani will receive 12.5M ClearOne shares for 59.4%–67.5% ownership; ClearOne will rename to Cortigent Holdings (CRGT), expected to close Q3 2026.

$VANIMedAI 8/10

Vivani Medical, Inc.: Vivani Announces Entry into Merger Agreement Between Wholly Owned Subsidiary Cortigent, Inc. and Nasdaq-listed ClearOne, Inc.

Vivani Medical (Nasdaq: VANI) said its subsidiary Cortigent will merge into ClearOne (Nasdaq: CLRO) via a definitive agreement, making Cortigent a wholly owned ClearOne unit. ClearOne plans a concurrent $10m–$15m financing. Vivani will receive 12.5m ClearOne shares and own 59.4%–67.5%; the combined company will trade as CRGT, expected to close Q3 2026.